Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Debt / NOTE 3.250%11/0
-
Market price (% of par)
-
95.24%
-
Total 13F principal
-
$210,113,838
-
Principal change
-
-$8,680,635
-
Total reported market value
-
$200,080,896
-
Number of holders
-
22
-
Value change
-
-$8,472,347
-
Number of buys
-
6
-
Number of sells
-
6
Institutional Holders of THERAVANCE BIOPHARMA INC - NOTE 3.250%11/0 as of Q2 2021
As of 30 Jun 2021,
THERAVANCE BIOPHARMA INC - NOTE 3.250%11/0 was held by
22 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$210,113,838
in principal (par value) of the bond.
The largest 10 bondholders included
Farallon Capital Management LLC, CITADEL ADVISORS LLC, HIGHBRIDGE CAPITAL MANAGEMENT LLC, BAUPOST GROUP LLC/MA, Aequim Alternative Investments LP, OAKTREE CAPITAL MANAGEMENT LP, TENOR CAPITAL MANAGEMENT Co., L.P., CAPSTONE INVESTMENT ADVISORS, LLC, ZAZOVE ASSOCIATES LLC, and MORGAN STANLEY.
This page lists
22
institutional bondholders reporting positions
for the Q2 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.